Home >
News Room Articles > dr. william smoyer honored with c. robert kidder endowed chair in clinical and translational research

Dr. William Smoyer Honored with C. Robert Kidder Endowed Chair in Clinical and Translational Research

William E. Smoyer, MD, was honored recently with the C. Robert Kidder Endowed Chair in Clinical and Translational Research in The Research Institute at Nationwide Children’s Hospital. For clinicians and researchers working in academic-medical institutions like Nationwide Children’s, endowed chairs represent the most prestigious and significant recognition of their work.

Smoyer was named vice president for Clinical and Translational Research and director of the Center for Clinical and Translational Research in The Research Institute at Nationwide Children’s last October. Prior to joining the faculty at Nationwide Children’s, he held the Robert C. Kelsch Chair in Pediatric Nephrology at the University of Michigan. As a basic and clinical scientist, Smoyer holds numerous grants from the National Institutes of Health which fund research related to nephritic syndrome and podocyte biology. He is a co-founder of the Renal Replacement Therapy Kinetics Study Group and the Midwest Pediatric Nephrology Consortium. Both organizations offer collaborative opportunities for renowned scientist/clinicians to implement and evaluate clinical and translational research initiatives. Smoyer is the author or co-author of more than 60 peer-reviewed publications and book chapters and is a member of the Society of Pediatric Research and the American Society of Pediatric Nephrology, as well as a fellow in the American Academy of Pediatrics.

“The entire purpose of doing research on human illness is to gain new knowledge to improve the health of children and adults in our society,” Smoyer said. “And clinical and translational research is the mechanism by which we take new knowledge or generate new knowledge and apply it in ways that result in improved health in the community.”

C. Robert Kidder co-founded 3Stone Advisors LLC in 2006, managing the 3Stone Inflection Fund and providing investment banking services to mid-market businesses. He joined an affiliated firm, Stonehenge Partners, Inc., as a principal and partner in 2004. Prior to Stonehenge, Kidder was chairman and CEO of Borden, Inc. from 1995 through 2001. That year, Borden Chemical merged with Borden, Inc., and Kidder continued as chairman of Borden Chemical, Inc. until 2003. He currently serves on the boards of directors of Morgan Stanley and Schering-Plough. He is on the boards of trustees of Nationwide Children’s Hospital and Ohio University and is president of the Wexner Center Board.